Landos Biopharma Announces Appointment of Fabio Cataldi, MD, as Chief Medical Officer
06 Septiembre 2022 - 6:00AM
Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage
biopharmaceutical company developing novel, oral medicines for
patients with autoimmune diseases, today announced the appointment
of Fabio Cataldi, MD, as the Company’s Chief Medical Officer,
effective September 5, 2022.
“We are thrilled to welcome Fabio to Landos, and look forward to
benefitting from his extensive clinical and drug development
experience as we finalize our portfolio review and execute a
focused plan to pursue what we believe are the Company’s most
promising molecules and target indications,” said Greg Oakes,
President and Chief Executive Officer of Landos. “Fabio’s clinical
and research expertise in gastroenterology and immunology,
particularly in ulcerative colitis (UC), will be integral as we
look to advance NX-13 following our recent announcement of positive
top-line results from our Phase 1b trial in UC patients.”
Dr. Cataldi joins Landos with more than twenty years of
successful experience in the development and commercialization of
innovative therapies. He brings deep clinical, medical and
scientific knowledge and expertise in immunology and
gastroenterology, having served in senior research and development
roles at Arena Pharmaceuticals, AbbVie, Shire, Pfizer, Biogen and
Novartis. Most recently, Dr. Cataldi served as Arena’s Vice
President and Therapeutic Area Head Gastroenterology, where he
helped lead the development of etrasimod, until its sale to Pfizer
for nearly $7 billion.
“Fabio’s appointment as Chief Medical Officer is an important
step as we look to continue selectively growing our leadership team
with the talent and expertise that we need to successfully advance
our pipeline. We are in the final stages of reviewing our clinical
development plans, and are planning to provide a comprehensive
update later this year,” continued Mr. Oakes.
“I am excited to join Landos at such a pivotal time for the
Company,” said Dr. Cataldi. “Having spent the majority of my career
focused on immunology and gastroenterology drug development, I am
looking forward to leveraging my background and experience as I
work with Greg and the leadership team to build on Landos’ strong
clinical foundation and deliver on its mission of addressing the
therapeutic gap for patients with autoimmune diseases.”
About Fabio Cataldi, MDDr. Cataldi has over
twenty years of diverse and extensive experience in medicine and
drug development in the United States and Italy. He most recently
served as Vice President and Therapeutic Area Head of
Gastroenterology at Arena Pharmaceuticals, where he led the
development of etrasimod in inflammatory bowel disease (IBD) and
other gastrointestinal (GI) indications and expanded the immunology
portfolio. Prior to joining Arena Pharmaceuticals, Dr. Cataldi
served as Team Lead of Gastroenterology and Immunology in Global
Pharmaceutical Research and Development at AbbVie. Previously, Dr.
Cataldi worked at Shire as Vice President of Clinical Development
in Internal Medicine/Gastroenterology, where he led the expansion
of the IBD portfolio with the out licensing of the anti-MAdCAM
antibody from Pfizer. Before Shire, Dr. Cataldi served as Pfizer’s
Senior Director of Gastroenterology Biotherapeutics Clinical
Programs in Worldwide R&D, where he led the expansion of the
Immunology and GI portfolio with assets targeting multiple diseases
beyond IBD, including rheumatoid arthritis, systemic lupus
erythematosus and dermatology conditions. Earlier in his career,
Dr. Cataldi held roles at: Biogen Idec, where he oversaw the
approval and launch of Tysabri in Crohn’s Disease; Novartis, where
he supported the launch of Zelnorm for treatment of irritable bowel
syndrome with constipation; Solvay Pharmaceuticals, where he helped
with the New Drug Admission process with the U.S. Food and Drug
Administration for Creon; and Beth Israel Deaconess Medical Center
in Boston, MA.
Dr. Cataldi holds an MD from the Second University of Naples
(SUN) in Medicine and Surgery.
About Landos BiopharmaLandos Biopharma is a
clinical-stage biopharmaceutical company focused on the discovery
and development of oral therapeutics for patients with autoimmune
diseases. We believe we were the first to identify and target
LANCL2, NLRX1 and PLXDC2, which are immunometabolic pathways or
targets. We have identified seven novel immunometabolic pathways or
targets based on predictions of immunometabolic function using a
proprietary advanced artificial intelligence-based integrated
computational and experimental precision medicine platform. Our
near-term focus is on our clinical-stage programs including
omilancor for the treatment of UC, NX-13 for the treatment of UC,
and LABP-104 for the potential treatment of systemic lupus
erythematosus and rheumatoid arthritis.
For more information, please visit www.landosbiopharma.com.
Cautionary Note on Forward-Looking Statements
Statements in this press release about future expectations, plans
and prospects for Landos Biopharma, Inc. (the “Company”), including
statements about the Company’s strategy, clinical development and
regulatory plans for its product candidates, including NX-13, and
other statements containing the words “anticipate”, “plan”,
“expect”, “may”, “will”, “could”, “believe”, “look forward”,
“potential”, the negatives thereof, variations thereon and similar
expressions, or any discussions of strategy constitute
forward-looking statements. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors, including: the uncertainties inherent
in the initiation and enrollment of future clinical trials,
expectations of expanding ongoing clinical trials, availability and
timing of data from ongoing clinical trials, expectations for
regulatory approvals, other matters that could affect the
availability or commercial potential of the Company’s product
candidates and other similar risks. Risks regarding the Company’s
business are described in detail in the Company’s filings with the
Securities and Exchange Commission (“SEC”), including in its Annual
Reports on Form 10-K and Quarterly Reports on Form 10-Q, which are
available on the SEC’s website at www.sec.gov. Additional
information will be made available in other filings that the
Company makes from time to time with the SEC. Such risks may be
amplified by the impacts of the COVID-19 pandemic. In addition, the
forward-looking statements included in this press release represent
the Company’s views only as of the date hereof. The Company
anticipates that subsequent events and developments will cause the
Company’s views to change. However, while the Company may elect to
update these forward-looking statements at some point in the
future, the Company specifically disclaims any obligation to do so,
except as may be required by law. These forward-looking statements
should not be relied upon as representing the Company’s views as of
any date subsequent to the date hereof.
Contacts
Tanner Kaufman / Kara SperryJoele Frank, Wilkinson Brimmer
Katcher212-355-4449
Landos Biopharma (NASDAQ:LABP)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Landos Biopharma (NASDAQ:LABP)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024